XML 31 R36.htm IDEA: XBRL DOCUMENT v2.4.0.8
LICENSE AGREEMENTS (Details Textual) (USD $)
3 Months Ended 9 Months Ended 12 Months Ended 1 Months Ended 1 Months Ended 3 Months Ended 9 Months Ended 3 Months Ended 9 Months Ended
Sep. 30, 2014
Sep. 30, 2013
Sep. 30, 2014
Sep. 30, 2013
Dec. 31, 2012
Dec. 31, 2013
Jun. 23, 2014
Ligand [Member]
Jun. 23, 2014
Ligand [Member]
Maximum [Member]
Jun. 23, 2014
Ligand [Member]
Minimum [Member]
Jun. 23, 2014
Opus Point Partners, Llc [Member]
Jun. 23, 2014
Opus Point Partners, Llc [Member]
Maximum [Member]
Sep. 22, 2014
Rhizen [Member]
Sep. 30, 2014
Rhizen [Member]
Sep. 30, 2014
Rhizen [Member]
Sep. 30, 2014
Research and Development Expense [Member]
Ligand [Member]
Sep. 30, 2014
Research and Development Expense [Member]
Rhizen [Member]
Sep. 30, 2014
Research and Development Expense [Member]
Rhizen [Member]
License Agreement [Line Items]                                  
License revenue $ 38,096 $ 38,096 $ 114,286 $ 114,286                          
Deferred Revenue 1,714,000   1,714,000     1,829,000                      
Additional Amount Receivable On Achievement Of Pre Specified Milestones     5,000,000                            
Income taxes         330,000                        
Business Acquisition Purchase Agreement Period Description     license revenue on a straight-line basis over the life of the agreement, which is through the expiration of the last licensed patent right or 15 years after the first commercial sale of a product in such country, unless the agreement is earlier terminated                            
Proceeds from Fees Received         2,000,000                        
Stock Issued During Period, Shares, Issued for Services             125,000                    
Non Cash Stock Expense 4,138,844 0 5,350,094 0                     1,211,250 4,100,000 4,100,000
Maximum Potential Payments Payable             207,000,000                    
Royalty payment Effective Percentage               9.50% 6.00% 1.00%              
Maximum sales for royalty expense               1,000,000,000     1,000,000,000            
Deferred Revenue, Current 152,381   152,381     152,381                      
Payments to Acquire Interest in Joint Venture                       4,000,000          
Shares, Issued                       371,530          
Future Potential Milestone Based Payments                       175,000,000          
Other Research and Development Expense $ 8,352,154 $ 3,138,119 $ 13,197,183 $ 9,014,776                 $ 4,000,000 $ 4,000,000